



# Partnering with pharmacy teams to improve migraine management

#### Realistic Medicine in Practice

- Dr Callum Duncan: Consultant Neurologist
- Dr David Watson: GP with Special Interest in Headache
- Abigail Duthie: Community Pharmacist
- Katy Styles: NMAHP Lead for Realistic Medicine
- Susan Flannery: Project Manager Realistic Medicine







# **Spotlight Session Overview**

- Project background and approach
  - Innovators & improvers
- Migraine awareness and recognition
  - Personalised approach to care
  - Better managing risk
- New Scottish Headache Pathway
  - Reducing unwarranted variation
  - Reducing waste/harm
- Putting it into practice
  - Shared decision making
  - Personalised approach to care
- Summary
- Q&A









#### Project bid:

- Upskill 50 pharmacists on migraine management
- Produce materials for 132 pharmacies
- Deliver a "manage your migraine" patient webinar





# The project approach

- Collaboration with pharmacists to identify
  - Learning needs
  - Practical considerations
  - Relevance to pharmacy team
- Engagement with people living with migraine
  - What Matters To You?
  - Had they accessed pharmacy for support?
  - Enablers to this.
  - Feedback has shaped training, public awareness campaign and webinar

10 pharmacists at focus group

23 survey responses

16 patients at

162 survey responses





## Milestones & Outputs

- Focus group & survey- pharmacists
- Focus group & survey people living with migraine
- Turas migraine landing page including eLearning module
- https://learn.nes.nhs.scot/71957
- Resources (posters, card, headache webpage)
- Four live training sessions in September
- Follow up survey & Q&A session (December)
- Manage Your Migraine webinar event (January)







30% of community pharmacists in NHS Grampian



27% of prescribing pharmacists in NHS Grampian

The following is a summary of known outcomes and impact to date:




individuals have engaged with the eLearning (11/10/2023 figure)




73
individuals have attended the live training sessions



'I feel confident dealing with people with migraine in my work'











### Realistic Medicine Pillars

- Personalised approach
- BUILD A **PERSONALISED** APPROACH TO CARE?
- By listening to the patient to better understand
  - the most bothersome symptoms
  - the individual and family burden
- Better Risk Management
  - Enabling all members of the pharmacy team
    - To have the tools to make the correct diagnosis
    - To have the knowledge to explain the diagnosis









## Migraine is a highly prevalent condition







Migraine is the **third most common** health condition in the world<sup>1</sup>

In the UK, more people live with migraine than diabetes, asthma and epilepsy combined<sup>2</sup>

Around **1 in 4 adults** aged 15–49 in the UK are living with migraine<sup>3</sup>



aged 15-49<sup>+2</sup>



#### What is the individual burden of migraine?

Migraine impacts multiple aspects of patients' lives



Emotional and mental health issues are common in migraine patients

Mood change and anxiety disorders

2–5 times more common in patients with migraine than in the general population<sup>3</sup>

<sup>1.</sup> The Migraine Trust. State of the Migraine Nation Dismissed for too long: Recommendations to improve migraine care in the U.K. September 2021, https://migrainetrust.org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-improve-migrainetrust-org/wp-content/uploads/2021/09/Dismissed-for-too-long\_Recommendations-to-i



## The cost of migraine





In the UK, the **direct** healthcare costs of migraine are estimated to be around £1 billion per year<sup>1</sup>



86 million equivalent workdays are lost per **year** in the UK due to migraine-related absenteeism and presenteeism<sup>1</sup>



productivity due to migraine accounts for an estimated indirect cost of £8.8 billion per year<sup>1</sup>

\*The level-3 grouping of headache disorders in the GBD Study 2019 includes only specific diseases: migraine and tension-type headache, each with medication overuse headache as a sequela factored in according to the proportion of MOH attributed to it<sup>2</sup>; †Expressed as years lived with disability<sup>2</sup>. GBD, Global Burden of Disease; MOH, medication overuse headache.

The level-3 grouping of headache disorders in the GBD Study 2019 includes only specific diseases: migraine and tension-type headache, each with medication overuse headache as a sequela factored in according to the proportion of MOH attributed to it<sup>2</sup>; 'Expressed as years lived with disability<sup>2</sup>. GBD, Global Burden of Disease; MOH, medication overuse headache.





## So, what is migraine?

Migraine is a neurological condition which features amplification of a number of sensory pathways<sup>1</sup>. Some studies suggest that genetic components contribute to susceptibility to the condition<sup>5</sup>.

- May be lifelong but varies in impact, severity and frequency throughout life (epigenetics)<sup>2</sup>
- Is a spectrum condition; attacks may be mild, moderate or severe<sup>1</sup>
- Can lead to attacks which may start at any age; usually in early adulthood<sup>3</sup>
- Has a natural history, often eventually improving with age<sup>2</sup>
- Migraine is NOT just a bad headache<sup>4</sup>





#### Headache disorders criteria for migraine: ICHD 3

#### A. At least five attacks fulfilling criteria B-D

B. Headache attacks lasting 4-72 hr (untreated or unsuccessfully treated)

#### C. Headache has at least two of the following four characteristics:

- unilateral location
- pulsating quality
- moderate or severe pain intensity
- aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs

#### D. During headache at least one of the following:

- nausea and/or vomiting
- photophobia and phonophobia
- E. Not better accounted for by another ICHD-3 diagnosis


1. IHS Classification ICHD-3 Available at: https://ichd-3.org/1-migraine/1-1-migraine-without-aura/.Last accessed: September 2023



## Migraine pathophysiology



- Migraine is a cyclic disorder with a complex sequence of symptoms within every headache attack.
- In its episodic form, migraine is characterised by recurrent attacks involving different phases, with a complex sequence of symptoms within every phase<sup>1</sup>.
- Significant advances have been made in characterising migraine as a brain disorder and in identifying evolutive functional changes in different brain areas during the different phases of a migraine attack<sup>1</sup>.








#### A landmark study found that most primary headache is migraine

#### Study design:

- Prospective open label study
- 128 practices, in 15 countries
- 1203 male and female patients

#### Inclusion criteria:

- Age 18-65 years
- Consulted their physician with a headache as a primary or secondary complaint
- Conclusion: "consider all disabling episodic primary headache with a normal physical examination to be migraine"



 A new clinic diagnosis of migraine was almost always correct: 98% of patients with a clinic diagnosis of migraine had IHS-defined migraine

 Of patients with non migraine diagnosis of primary headache, diary evidence showed 82% had IHS-defined migraine





#### Diagnosing migraine: 3 questions to ask about the WORST attacks

- A study evaluated validity and reliability of a brief, selfadministered migraine screener in patients with headache complaints in the primary care setting
- Nausea, photophobia, and headache-related disability had a strong and significant association with diagnosis of migraine
- Individual screeners items were:
- 1. Has a headache limited your activities for a day or more in the last three months?
- 2. Are you nauseated or sick to your stomach when you have a headache?
- 3. Does light bother you when you have a headache?

Yes to 2 answers has diagnostic sensitivity of 0.81

Yes to **3** answers has a positive predictive value of 0.93

• Lipton RB, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003;61(3):375-82.






### **Need for a National Headache Pathway**





4.4 % of GP consultations are for headache, 1:50 referred to secondary care 20-25% of referrals into neurology clinics, 1-2% of acute presentations to ED



Under-recognised and often inappropriately treated with analgesics, current acute and preventative treatment are underused, new treatments coming on-line



National (SIGN / SMC / BASH) and Local Guidance available



Variation in practice between and within different heath boards



Appropriate early management of headache in primary care (Community Pharmacy and General Practice) may improve treatment, prevent complications and reduce need for secondary care referral






## Migraine Management

- Modifiable lifestyle triggers
- Acute treatment
- Prevent Medication Overuse Headache
- Preventative treatment
  - Accessed from primary care
  - Accessed from secondary care





# Scottish National Headache Pathway 7 sections with 2 additional in development





# What is the Right Decision Service?

Single national "mega-app" for Scotland which aims to:

Provide easy access to evidence-based guidance


Save time for healthcare professionals

Improve patient safety + experience

Reduce variation, waste + harm

Empower patients to make informed decisions









### **Target Audience**



- Primary aim of the National Headache Pathway is to provide guidance to primary care (general practice)
- Headache care is, however, accessed across the NHS

Community Pharmacy

General Practice

Secondary care - ED/Acute Medicine, Neurology





- Community Pharmacy
  - Timely correct diagnosis
  - Appropriate acute treatment
  - Avoid Medication Overuse Headache
  - Redirect patients with potentially concerning headache
- Practice Pharmacist
  - Better preventative treatment management





Correct initial treatment may prevent the development of Chronic Migraine





# **Community Pharmacy Impact**








# A Few Examples of Patient consultations

- Straight forward diagnosis
- Red-Flag symptoms
- Advice and counselling on new migraine medications
- Advice about OTC NSAID's











# Watch this space... Phase 2

- Further 12 months: January 2024 January 2025
- Embedding in NHS Grampian
  - Nurture pharmacy expertise for sustainability
- Undergraduate education
- Expanding to (min) three other health boards
- Testing approach in another pathway